| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/05/2000 | EP1016411A1 Sulodexide for restenosis therapy |
| 07/05/2000 | EP1016410A1 Glycosaminoglycans for the treatment for pre-eclampsia and related diseases |
| 07/05/2000 | EP1015884A1 Methods of identifying molecules that home to angiogenic vasculature in tumors |
| 07/05/2000 | EP1015607A1 Dna encoding a ras carboxyl-terminal processing protein |
| 07/05/2000 | EP1015602A1 Glutrna gln amidotransferase - a novel essential translational component |
| 07/05/2000 | EP1015585A2 Tie ligand homologues |
| 07/05/2000 | EP1015578A1 Therapeutic molecules |
| 07/05/2000 | EP1015566A1 Human ste20-like stress activated serine/threonine kinase |
| 07/05/2000 | EP1015492A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 07/05/2000 | EP1015487A2 Ligands for discoidin domain receptor tyrosine kinases and complexes thereof |
| 07/05/2000 | EP1015471A1 Hypoxia-regulated genes |
| 07/05/2000 | EP1015422A1 Hiv matrix protein tyrosine position 29 pocket binders |
| 07/05/2000 | EP1015038A1 Methods for the detection, treatment, and prevention of neurodegeneration |
| 07/05/2000 | EP1015032A2 High viscosity liquid controlled delivery system as a device |
| 07/05/2000 | EP1015031A1 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| 07/05/2000 | EP1015022A1 New improved formulation for treatment of thromboembolism |
| 07/05/2000 | EP1015020A1 Pharmaceutical substance containing various vitamin k-dependent factors |
| 07/05/2000 | EP1015012A1 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| 07/05/2000 | EP1015008A1 Compounds and compositions for delivering active agents |
| 07/05/2000 | EP1015002A1 Metal compounds, mixed or sulphated, as phosphate binders |
| 07/05/2000 | EP1014995A1 Compositions and methods for preventing restenosis following revascularization procedures |
| 07/05/2000 | EP1014989A1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 07/05/2000 | EP1014986A1 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST |
| 07/05/2000 | EP1014981A1 Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime |
| 07/05/2000 | EP1014977A1 Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes |
| 07/05/2000 | EP1014971A1 Treatment for premenstrual dysphoric disorder |
| 07/05/2000 | EP1014970A1 Parasiticidal formulations |
| 07/05/2000 | EP1014965A1 Dietary compositions for enhancing metabolism and alleviating oxidative stress |
| 07/05/2000 | EP1014961A1 Improved treatment of migraine headache |
| 07/05/2000 | EP1014950A1 Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof |
| 07/05/2000 | EP1014945A1 Cationic lipid compositions targeting angiogenic endothelial cells |
| 07/05/2000 | EP1014942A1 Non-steroidal antiinflammatory drug formulations for topical application to the skin |
| 07/05/2000 | EP1014940A1 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 07/05/2000 | EP1014886A1 Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
| 07/05/2000 | EP1014791A1 Method for lowering serum lipid levels employing an mtp inhibitor in combination with another cholesterol lowering drug |
| 07/05/2000 | EP0759754A4 A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain |
| 07/05/2000 | EP0637241B1 Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| 07/05/2000 | CN1259126A Pharmacological agents |
| 07/05/2000 | CA2257804A1 Treatment of hiv-associated dysmorphia/dysmetabolic syndrome |
| 07/04/2000 | US6083985 Medicinal composition |
| 07/04/2000 | US6083980 3b,7,9a-trimethyl-1,3,3a,3b,4,5,5a,6,9,9a,9b,10,11,11a-tetrade cahydro phenanthro(1,2-c)furan derivative used as immunosuppressant to prevent grafting rejection |
| 07/04/2000 | US6083973 Methods for inhibiting mucin secretion using RAR α selective antagonists |
| 07/04/2000 | US6083924 DnaB of staphylococcus aureus |
| 07/04/2000 | US6083920 Treating nervous system disorders by administering lysocerebroside or lysosphingomyelin |
| 07/04/2000 | US6083906 Method of regulating nitric oxide production or arthritis with soluble IL-17 receptor |
| 07/04/2000 | US6083711 Proteases compositions capable of binding to said site, and methods of use thereof |
| 07/04/2000 | US6083706 Inhibitors of leaderless protein export |
| 07/04/2000 | US6083705 Screening for chemical compound which preferentially binds to binding protein; incubation of compound with cells expressing binding protein, detecting preferential binding of compound to surface of cell not normally expressing binding protein |
| 07/04/2000 | US6083521 Drugs and polyethylene carbonates |
| 07/04/2000 | US6083518 Bactericide cleaning compounds with surfactants |
| 07/04/2000 | US6083515 Treating inflammation, pain, gastrointestinal lesions or fever in an animal in need thereof with reduction of the gastrointestinal toxicity or renal toxicity of the nonsteroidal antiinflammatory drug |
| 07/04/2000 | US6083502 Methods for detecting the antigen and its expression level as an indication of the presence of tumor cells |
| 07/04/2000 | US6083495 Method of making phosphate-binding polymers for oral administration |
| 07/04/2000 | US6083483 For the modulation of the motility and peristalsis of the hollow organs of the urogenital and gastrointestinal tract |
| 07/04/2000 | CA2169356C Phosphate-binding polymers for oral administration |
| 06/30/2000 | CA2293890A1 A novel treatment for pre-eclampsia and related diseases |
| 06/29/2000 | WO2000037944A1 Kidney disease detection and treatment |
| 06/29/2000 | WO2000037943A1 Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase |
| 06/29/2000 | WO2000037685A2 Method of identifying a psychotropic agent using differential gene expression |
| 06/29/2000 | WO2000037679A2 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 06/29/2000 | WO2000037676A1 Method of sequence identification |
| 06/29/2000 | WO2000037640A2 Compositions and methods for the treatment of tumor |
| 06/29/2000 | WO2000037639A2 Lymphocytic membrane proteins |
| 06/29/2000 | WO2000037620A1 Crystalline form of activated trap and use thereof for structure-based drug design |
| 06/29/2000 | WO2000037616A1 Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders |
| 06/29/2000 | WO2000037502A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 06/29/2000 | WO2000037489A2 Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same |
| 06/29/2000 | WO2000037483A1 Protein-protein interactions in neurodegenerative disorders |
| 06/29/2000 | WO2000037455A1 Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| 06/29/2000 | WO2000037444A1 Compounds useful in the treatment of inflammatory diseases |
| 06/29/2000 | WO2000037141A1 Combination chemotherapy |
| 06/29/2000 | WO2000037124A1 Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 06/29/2000 | WO2000037112A1 Pharmaceutical compositions comprising immortalised endothelial cells |
| 06/29/2000 | WO2000037107A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |
| 06/29/2000 | WO2000037089A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity |
| 06/29/2000 | WO2000037085A1 Treatment of diseases involving cyst formation |
| 06/29/2000 | WO2000037077A1 Assays for ligands for nuclear receptors |
| 06/29/2000 | WO2000037076A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer |
| 06/29/2000 | WO2000037075A1 Combination of an at1 angiotensin ii receptor antagonist and an immunosuppressant |
| 06/29/2000 | WO2000037073A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome |
| 06/29/2000 | WO2000037072A1 Use of inhibitors of gag synthesis for the treatment of corneal haze |
| 06/29/2000 | WO2000037071A1 Topical treatment of skin disease |
| 06/29/2000 | WO2000037068A1 Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 06/29/2000 | WO2000037067A2 Sensitizing agents for the treatment of skin lesions |
| 06/29/2000 | WO2000037066A2 A method for the prophylactic treatment of cataracts |
| 06/29/2000 | WO2000037065A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 06/29/2000 | WO2000037061A2 cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION |
| 06/29/2000 | WO2000037053A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 06/29/2000 | WO2000037052A1 Pulmonary drug delivery |
| 06/29/2000 | WO2000037051A1 Aerosol formulations for buccal and pulmonary application |
| 06/29/2000 | WO2000037037A2 Composition for treatment of burns |
| 06/29/2000 | WO2000037027A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system |
| 06/29/2000 | WO2000037026A1 Dihydropyrimidines and uses thereof |
| 06/29/2000 | WO2000037022A2 Combination therapy for the treatment of sepsis |
| 06/29/2000 | WO2000036918A1 Methods and compositions for treatment of cell proliferative disorders |
| 06/29/2000 | WO2000036915A1 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| 06/29/2000 | WO2000024437A8 Textured and porous silicone rubber |
| 06/29/2000 | WO2000012113A3 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions |
| 06/29/2000 | WO2000009073A3 Blood-brain barrier therapeutics |
| 06/29/2000 | WO2000006737A3 Streptococcus pneumoniae proteins and nucleic acid molecules |